INSTRUCTIONS ON MANAGEMENT OF THE ANTIBIOTIC USE IN HOSPITALS
The Minister of Health has issued the Decision No. 772/QD-BYT dated March 04, 2016 on issuing the “Instructions on management of the antibiotic use in hospitals”, medicine and Treatment Council provides counsels to the hospital's leadership to make decisions on the establishment of the body for management of the use of antibiotics in the hospital and on the missions assigned to each of its members, whose roles and mutual supports must be defined. The constituents of the antibiotic management body, the main members are bacterial disease/clinical doctors, clinical pharmacists, microbiologists, bacterial contamination control specialists, representatives of General planning faculty and Quality control faculty and other members are nurses, information technology specialists and personnel of the patient safety committee (if any).
The antibiotic management body must have contributions to the establishment of regulations on the management of the use of antibiotics in the hospital, as participate in the establishment of guidelines for the use of antibiotics; participate in the making of the list of antibiotics requiring medical consultation before prescription; participate in the establishment of the list of antibiotics ratified before use, prescription request form and procedures for the ratification of such antibiotics; participate in the development of guidelines for treatments against bacterial diseases commonly found in a hospital; participate in the preparation of documents and guidelines for clinical microbiology.
Other important content prescribed at this Decision is the Guidelines for choice of antibiotics. Accordingly, the choice of antibiotics is subject to the characteristics of the pathogen and patient, positions of bacterial infections, pharmacokinetics, pharmacodynamics and drug resistance model; clear indications of bacteria and results of antibiotic susceptibility tests facilitate the choice of the best effective and least virulent antibiotic that has the narrowest spectrum in correlation with the pathogens identified; de-escalate antibiotic treatment according to antibiotic susceptibility tests; prioritize 01 type of antibiotics according to antibiotic susceptibility tests; combine antibiotics only to intensify the destruction of bacteria, decrease the possibility of resistant species appearing and treat infections caused by various types of bacteria.
This Decision takes effect on the signing date.
